Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 90357-06-5
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Bag,Drum
Delivery Time: 7-15 days
Payment Terms: L/C, D/A, T/T, Western Union
Supply Ability: TON
CAS NO:: |
90357-06-5 |
Appearance:: |
Off-white Crystalline Solid |
Molecular Formula:: |
C18H14F4N2O4S |
Molecular Weight:: |
430.37300 |
EINECS NO:: |
618-534-3 |
MDL NO:: |
MFCD00869971 |
CAS NO:: |
90357-06-5 |
Appearance:: |
Off-white Crystalline Solid |
Molecular Formula:: |
C18H14F4N2O4S |
Molecular Weight:: |
430.37300 |
EINECS NO:: |
618-534-3 |
MDL NO:: |
MFCD00869971 |
Product Description:
Product Name: Bicalutamide CAS NO: 90357-06-5
Synonyms:
N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide;
Cosudex;
BicalutaMide API;
Chemical & Physical Properties:
Appearance: Off-white crystalline solid
Assay :≥99.0%
Density: 1.52 g/cm3
Boiling Point: 650.3℃ at 760 mmHg
Melting Point: 191-193℃
Flash Point: 347.1℃
Refractive Index: 1.577
Storage Condition: Store in original container in a cool dark place.
Safety Information:
Hazard Class: 9
Safety Statements: S26; S36
HS Code: 2929909090
Packing Group: III
RIDADR: 3077
Risk Statements: R36/37/38
Hazard Code: Xi
Non-steroi-dal peripherally active antiandro-gen. Used as an antiandro-gen, antineoplastic (hormonal). Bicalutamide was launched in the United Kingdom, its first worldwide market, for the treatment of advanced prostate cancer in combination with an LHRH analog or surgical castration. A non-steroi-dal, peripherally selective antiandro-gen, bicalutamide inhibits the action of dihydrotestostero-ne and testostero-ne at target sites by competitive binding to the cytosolic andro-gen receptor. It was reportedly well tolerated with no significant cardiovascular and metabolic side effects due to the benefit of lacking any steroi-d activity. The efficacy of bicalutamide as a monotherapy has been demonstrated clinically. Promising response rates were also reported in treating colorectal, breast, pancreas and non-small cell lung cancers.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.